SPYRE THERAPEUTICS, INC.: cashflow_financing
| Value | {"amount": 10000, "concept": "us-gaap:NetCashProvidedByUsedInFinancingActivities", "currency": "USD"} |
|---|---|
| Period | 2023-01-01 – 2023-03-31 |
| Status | current |
| Entity | SPYRE THERAPEUTICS, INC. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T16:49:38.245373+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/06cbf21b-42b4-4965-ade7-08e02e7e98de
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0000950170-23-020825 · Open the official SEC filing →Retrieved: 2026-08-19T16:49:38.245373+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001636282/cashflow-financing/2023-03-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/06cbf21b-42b4-4965-ade7-08e02e7e98de
History
- no predecessors — first report